TP53 and breast cancer: While pathogenic germline mutations of TP53 in Li Fraumeni syndrome patients are likely to represent the initial event in breast cancers of such patients (as well as other neoplasia in these patients), recent studies revealed that somatic TP53 mutations may arise at later stages of tumor evolution in many non-hereditary breast cancers [3, 4].